2 / 13
Page 11
Current Research: Integrative Medicine
CAM Therapies 2017
September 18-19, 2017 Charlotte, USA
5
th
International Meeting on
Complementary and Alternative Medicine & Therapies
Can curcumin overcome cancer chemo resistance?
Mutlu Demiray
KTO Karatay University, Turkey
C
urcuminwas first isolated almost two centuries ago. Since the time ofAyurveda numerous therapeutic activities
has been assigned to turmeric for a wide variety of diseases and conditions including those of the skin,
pulmonary, gastrointestinal system, pains, wounds, liver disorders and cancer. Its anticancer activity, comprising
the regulation of proliferation, survival, invasion, angiogenesis, and metastasis, has also been reported for several
types of cancer. Especially curcumin potentiates chemotherapeutic agent apoptotic effects. In other words
curcumin can overcome cancer chemo and radio resistance. Curcumin effect; Singh and Aggarwal have shown
that curcumin inhibits NF-5B activation pathway at a step before inhibitor kappa B alfa (I5B) phosphorylation.
Nuclear Factor- Kappa B (NF-5B) is a key inflammatory transcription factor expressed frequently in tumors.
Therewithal NF-kB has an important role of cellular processes such as proliferation, apoptosis, inflammatory
and immune response. Recent clinical studies have shown that significant NF-5B expression associated with
chemo and radiation resistance and poor outcome in several human cancers. Wu at al. has evaluated NF-5B in
the cancer patient outcome. This meta-analysis has shown that NF-5B overexpression is associated with worse
overall survival and disease free survival. Moreover, NF-5B expression was shown to be TNM stage independent
poor prognostic factor. Clinical studies that evaluated relationship between NF-5B and prognosis and treatment
outcome, were shown that NF-B is associated with poor prognosis and poor response. Also activation of the NF-5B
pathway renders many types of tumor cell more resistant to chemotherapy and radiotherapy, presumably via induction
of anti-apoptotic proteins which apoptosis induction is a major mechanism of the action of radiotherapy and most
chemotherapeutic agents. Inhibition of NF-5B activation seems to be promising option to improve the efficacy of
conventional anticancer therapies. Preclinical and clinical observations indicate that NF-5B plays an important
role in chemo and radio resistance and establishes the inhibition of NF-5B as a new approach in cancer treatment.
Also NF-5B plays an important role at the multiple cancer related pathways, especially MAPK. Because of
these specialities inhibition of NF-5B can potentiate tyrosine kinase inhibitors (TKI) effectiveness. Preclinical
data supports these hypothesis and our clinical experience led us think that curcumin is a good partner for TKI.
Preclinical
in-vivo
and
in-vitro
trials evaluated curcumin plus chemotherapeutic agent and TKIs combination.
These trials had shown that curcumin combination with radiotherapy, chemotherapies or TKIs were better than
each treatment alone. Preclinical and early clinical trials and our clinical experience which curcumin combination
with chemotherapy, radiotherapy, TKI experience more than 4 years, led us think that adds to curcumin standard
therapies (radio or chemotherapy or TKI) may cause better outcome. The best curcumin treatment regimen and
the best curcumin formulations is not determinant until today. Therewithal curcumin loaded nanoparticles more
effective than free curcumin. We might have got effective and safe partner of cancer treatment but we need more
effective curcumin formulations. Conclusion; Preclinical
in-vivo
and
in-vitro
trials, clinical trials data which some
of it came from us, shows that curcumin is very important adjunctive treatment agents are safe and inexpensive,
as long as we have to use chemotherapy, radiotherapy and TKI.
Biography
Mutlu Demiray is a Professor of Medical Oncology, KTO Karatay University and Medicana International Istanbul Hospital was born Turkey. After finishing
Medical School at Akdeniz University at 1995, he started internal medicine specialty at Uludag University- Bursa, Turkey, where he studied the relation between
gastric carcinogenesis and
Helicobacter pylori
. He finished his second specialty at Medical Oncology at 2004 while he was studying the levels of M30 and M65 at
neo-adjuvant therapy of breast cancer. He gainedAssociated Prof. degree at 2006 and he attended at the very first applications of parenteral curcumin formulations
with Dr. Huseyin Sahinbas at Germany, where he gained a lot of experiences about clinical use of curcumin. Getting Professor Degree in 2016 at KTO Karatay
University, he is producing free and nano-curcumin formulations at the Scientific and Technological Research Council of Turkey. He has recently developed a
new bio-available oral nano-formulation of curcumin with his colleagues.
drdemiray@gmail.com